Allogene Therapeutics, Inc.

Healthcare · Biotechnology · United States

Last price 1.18 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 407.68M

Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports

Allogene Therapeutics, Inc. a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer and autoimmune diseases. It develops a pipeline of multiple allogeneic CAR T cell product candidates utilizing protein engineering, gene editing, gene insertion, and advanced proprietary T cell manufacturing technologies. The company is also developing cemacabtagene ansegedleucel (cema-cel), an engineered allogeneic CAR T cell product candidate that targets CD19 for the ...